Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel™

Clinical and Translational Oncology

Volumn 15, Issue 1, 2013, Pages 26-32

  Madaan, Alka ^a   Singh, Pratibha ^a   Awasthi, Anshumali ^a   Verma, Ritu ^a   Singh, Anu T ^a   Jaggi, Manu ^a   Mishra, Shiva Kant ^c   Kulkarni, Sadanand ^c   Kulkarni, Hrishikesh ^b  

^a Dabur Research Foundations   (India)

^b Fresenius Kabi Asia Pacific Limited   (Hong Kong)

^c Evalueserve Private Limited   (India)

Author keywords

Delivery system; Intaxel; Nanoparticle; Naoxel; Paclitaxel; Tumor

Indexed keywords

CREMOPHOR; NANOMICELLE; NANOPARTICLE; NANOXEL; PACLITAXEL; POLYMER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NANOPHARMACEUTICS; OVARY CARCINOMA; PH MEASUREMENT; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY;

ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NANOPARTICLES; NEOPLASMS; PACLITAXEL;

EID: 84872371824     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0883-2     Document Type: Article

References (24)

1. Mo Y, Lim LY (2005) Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Release 108(2-3):244-262
2. Ebbesen M, Jensen TG (2006) Nanomedicine: techniques, potentials, and ethical implications. J Biomed Biotechnol 2006(5):51516
3. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL (2001) The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590-1598
4. Kloover JS, Den Bakker MA, Gelderblom H, van Meerbeeck JP (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90(2):304-305
5. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6(5):609-621
6. Skwarczynski M, Hayashi Y, Kiso Y (2006) Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J Med Chem 49(25):7253-7269
7. Brahmachari BH, Hazra A, Majumdar A (2011) Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: an observational study. Indian J Pharmacol. 43(2):126-130
8. Charoentum C, Thongprasert S, Chewasakulyong B (2007) Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer. Gan To Kagaku Ryoho 34(10):1603-1607
9. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res Off J Am Assoc Cancer Res 12(4):1317-1324
10. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A et al (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin Cancer Res 11(11):4136-4143
11. Fader AN, Rose PG (2009) Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer 19(7):1281-1283
12. Feng T, Szabo E, Dziak E, Opas M (2010) Cytoskeletal disassembly and cell rounding promotes adipogenesis from ES cells. Stem Cell Rev 6(1):74-85
13. Petrelli F, Borgonovo K, Barni S (2010) Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother 11(8):1413-1432
14. Sun X, Yan Y, Liu S, Cao Q, Yang M, Neamati N, et al (2011) 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 52(1):140-146
15. Huh JW, Kim HR (2009) Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0? J Surg Oncol 100(5):387-391
16. van Vlerken LE, Amiji MM (2006) Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 3(2):205-216
17. Wang SH, Lee CW, Chiou A, Wei PK (2010) Size-dependent endocytosis of gold nanoparticles studied by three-dimensional mapping of plasmonic scattering images. J Nanobiotechnology 8:33
18. Jin C, Bai L, Wu H, Tian F, Guo G (2007) Radiosensitization of paclitaxel, etanidazole and paclitaxel + etanidazole nanoparticles on hypoxic human tumor cells in vitro. Biomaterials 28(25):3724-3730
19. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590-1598
20. Liaudet L, Soriano FG, Szabo C (2000) Biology of nitric oxide signaling. Crit Care Med 28(4 Suppl):N37-N52
21. Jang SH, Wientjes MG, Lu D, Au JL (2003) Drug delivery and transport to solid tumors. Pharm Res 20(9):1337-1350
22. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249
23. Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res Official J Am Assoc Cancer Res 14(5):1310-1316
24. Singh AT, Jaggi M, Khattar D, Awasthi A, Mishra SK, Tyagi S et al (2008) A novel nanopolymer based tumor targeted delivery system for paclitaxel. J Clin Oncol 26(May 20 suppl; abstr 11095)